Aviat Networks (AVNW) Reaches $18.44 After 4.00% Down Move; Arena Pharmaceuticals (ARNA) Shorts Raised By 7.29%

May 17, 2017 - By Migdalia James

Arena Pharmaceuticals Incorporated (NASDAQ:ARNA) had an increase of 7.29% in short interest. ARNA’s SI was 8.89 million shares in May as released by FINRA. Its up 7.29% from 8.28 million shares previously. With 1.84 million avg volume, 5 days are for Arena Pharmaceuticals Incorporated (NASDAQ:ARNA)’s short sellers to cover ARNA’s short positions. The SI to Arena Pharmaceuticals Incorporated’s float is 3.67%. About 585,160 shares traded. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has risen 6.00% since April 17, 2017 and is uptrending. It has by 0.00% the S&P500.

The stock of Aviat Networks Inc (NASDAQ:AVNW) is a huge mover today! About 56,419 shares traded or 5.32% up from the average. Aviat Networks Inc (NASDAQ:AVNW) has risen 6.00% since April 17, 2017 and is uptrending. It has by 0.00% the S&P500.The move comes after 8 months negative chart setup for the $95.92M company. It was reported on May, 17 by Barchart.com. We have $17.70 PT which if reached, will make NASDAQ:AVNW worth $3.84 million less.

Aviat Networks, Inc., together with its subsidiaries, is a supplier of microwave networking solutions. The company has market cap of $95.92 million. The Company’s product categories include point-to-point microwave and millimeter wave radios that are licensed , lightly-licensed and license-exempt (operating in license-exempt frequencies), and element and network management software. It currently has negative earnings. In addition, it provides a range of professional services enabling it to deliver turnkey networks, including design, deployment, maintenance and managed services.

Arena Pharmaceuticals, Inc. is a biopharmaceutical company. The company has market cap of $369.88 million. The Firm is focused on developing small molecule drugs across a range of therapeutic areas. It currently has negative earnings. The Firm has three primary investigational clinical programs: etrasimod in Phase II evaluation for ulcerative colitis, APD371 entering Phase II evaluation for the treatment of pain associated with Crohn’s disease, and ralinepag (APD811) in Phase II evaluation for pulmonary arterial hypertension (PAH).

Among 3 analysts covering Arena Pharmaceuticals (NASDAQ:ARNA), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Arena Pharmaceuticals had 3 analyst reports since October 28, 2015 according to SRatingsIntel. On Wednesday, October 28 the stock rating was maintained by WallachBeth Capital with “Buy”. FBR Capital initiated Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) on Thursday, September 15 with “Outperform” rating. The rating was maintained by RBC Capital Markets with “Sector Perform” on Wednesday, November 11.

Since May 12, 2017, it had 1 buy, and 0 sales for $29,750 activity. Munshi Amit had bought 25,000 shares worth $29,750 on Friday, May 12.

Investors sentiment increased to 1.97 in 2016 Q4. Its up 0.79, from 1.18 in 2016Q3. It is positive, as 9 investors sold Arena Pharmaceuticals, Inc. shares while 25 reduced holdings. 19 funds opened positions while 48 raised stakes. 110.93 million shares or 6.74% less from 118.95 million shares in 2016Q3 were reported. Mufg Americas Corp accumulated 5,542 shares. Vanguard Gp Inc, Pennsylvania-based fund reported 18.99M shares. Connor Clark & Lunn Invest Mngmt Ltd accumulated 126,300 shares. Planning Corporation accumulated 15,450 shares or 0% of the stock. Fifth Third Bancorporation reported 750 shares. Moreover, Tiaa Cref Inv Management Limited Com has 0% invested in Arena Pharmaceuticals, Inc. (NASDAQ:ARNA). Senzar Asset Ltd Limited Liability Company has 0.71% invested in Arena Pharmaceuticals, Inc. (NASDAQ:ARNA). Sunbelt Securities Incorporated owns 350 shares. Bnp Paribas Arbitrage invested 0% in Arena Pharmaceuticals, Inc. (NASDAQ:ARNA). 434,153 were reported by Alliancebernstein L P. 220,748 are held by Blackrock Ltd. Sg Americas Ltd, a New York-based fund reported 98,919 shares. Tci Wealth Advsr has 500 shares. Citigroup has invested 0% in Arena Pharmaceuticals, Inc. (NASDAQ:ARNA). Schwab Charles Inv Mgmt accumulated 0% or 863,111 shares.